J&J announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding the Marketing Authorisation for Tremfya (guselkumab) to… read more.
Influencers are promoting “overwhelmingly” misleading information about medical tests on Instagram and TikTok, according to a global University of Sydney-led study published today in JAMA Network Open. Researchers analysed… read more.
Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate stomach problems. PPIs are activated in the acid-producing cells of… read more.
Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn’s disease receiving two years… read more.
AbbVie announced that the FDA has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. It is approved in combination with… read more.
Almost 50 million Americans—disproportionately in rural areas—must drive 25 miles or more to access a gastroenterologist for diagnosis and treatment of issues involving the digestive system, according to… read more.
A recent study1 from Purdue University scientists reveals following a consistent dietary pattern that features lean red meat can contribute to gut microbiota balance and support cardiovascular health. Balanced Diets… read more.
The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive drugs…. read more.
Eli Lilly and Company announced that the FDA has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved… read more.
A new Tulane University study suggests the Mediterranean diet’s brain-boosting benefits may work by changing the balance of bacteria in the gut. In a study published in Gut Microbes Reports, researchers… read more.
New research from Karolinska Institutet in Sweden highlights the potential benefits of screening people with type 2 diabetes for liver damage at the same time as they undergo… read more.
New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
